Treatment of Kras-Variant Cancers with Serotonin Transporter Inhibitors

Ovarian tumors with KRAS variant are resistant to treatment with standard chemotherapies including cisplatin
Yale scientists have discovered that serotonin transport inhibitors selectively inhibit KRAS-variant ovarian cancer.
This method can also be used to specifically treat other cancer, such as breast cancer, with KRAS–variant.
Intellectual property patent application pending